Aurora Cannabis Inc. has disclosed its openness to reviewing a bid from a U.S. cannabis entity aiming to acquire the Edmonton-headquartered company. The announcement of establishing a dedicated committee to evaluate the unsolicited offer was made by Aurora following Curaleaf Holdings Inc.’s revelation that it was gearing up to propose the acquisition of all shares of Aurora.
If successful, the proposed acquisition would lead to the formation of a unified cannabis enterprise operating in 17 countries across Europe, North America, and various other global markets, as stated by Curaleaf. The company, based in Stamford, Conn., and listed on the Toronto Stock Exchange, has decided to make its intentions public after unsuccessful attempts to engage in private discussions with Aurora’s leadership.
Curaleaf indicated that despite sending a formal letter of intent on June 23 and a subsequent follow-up letter on July 7 outlining its proposal, Aurora’s board declined to participate in discussions. Boris Jordan, Curaleaf’s CEO, expressed disappointment at Aurora’s lack of meaningful engagement and emphasized the significant premium and compelling strategic rationale behind the proposal.
In response to Curaleaf’s claims, Aurora confirmed receiving the letters but disputed assertions that it had rejected the offer outright. The Canadian company clarified that its lead independent director had communicated with Curaleaf’s CEO as recently as July 24, expressing a focus on executing its business plan in the short to medium term while remaining open to ongoing dialogue.
Aurora has announced the formation of a special committee comprising independent directors to assess the proposal’s alignment with stakeholders’ interests. However, the company cautioned that reaching a deal is not guaranteed and assured that its operations would continue uninterrupted during the evaluation process.
While acknowledging Curaleaf’s interest in pursuing the bid, analysts from TD Cowen, Derek Lessard, and Ryan Neal, asserted that the current offer undervalues Aurora’s long-term potential. They highlighted Aurora’s market leadership in medical cannabis, robust product portfolio, financial strength, and adeptness in navigating international regulatory landscapes as factors that could drive greater value creation over time.
Jordan emphasized the value creation potential of merging the companies, citing the synergy between Curaleaf’s global distribution network and Aurora’s established international medical cannabis presence. The combined revenue of the two companies over the past year exceeded $1.5 billion US, with Curaleaf anticipating annual cost synergies of at least $40 million US from the proposed takeover.
In summary, Jordan characterized the merger as mutually beneficial for shareholders of both Curaleaf and Aurora, offering Aurora shareholders an opportunity to partake in a diversified global platform and gain exposure to favorable U.S. regulatory trends.